TERN
Income statement / Annual
Last year (2023), Terns Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Terns Pharmaceuticals, Inc.'s net income was -$90.21 M.
See Terns Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$1.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$881,000.00 |
$1.03 M |
$512,000.00 |
$394,000.00 |
$195,000.00 |
$65,000.00 |
| Gross Profit |
-$881,000.00 |
-$1.03 M |
$488,000.00 |
-$394,000.00 |
-$195,000.00 |
-$65,000.00 |
| Gross Profit Ratio |
0 |
0 |
0.49 |
0 |
0 |
0 |
| Research and Development
Expenses |
$63.50 M
|
$39.62 M
|
$31.31 M
|
$28.03 M
|
$61.53 M
|
$14.55 M
|
| General & Administrative
Expenses |
$39.06 M
|
$22.41 M
|
$19.55 M
|
$9.00 M
|
$8.66 M
|
$3.90 M
|
| Selling & Marketing
Expenses |
-$881,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$39.06 M
|
$22.41 M
|
$19.55 M
|
$9.00 M
|
$8.66 M
|
$3.90 M
|
| Other Expenses |
$0.00 |
-$68,000.00 |
$40,000.00 |
-$2.79 M |
$154,000.00 |
$38,000.00 |
| Operating Expenses |
$102.56 M |
$62.03 M |
$50.86 M |
$37.03 M |
$70.20 M |
$18.46 M |
| Cost And Expenses |
$102.56 M |
$62.03 M |
$50.86 M |
$37.03 M |
$70.20 M |
$18.46 M |
| Interest Income |
$12.90 M |
$2.11 M |
$170,000.00 |
$55,000.00 |
$1.20 M |
$332,000.00 |
| Interest Expense |
$0.00 |
-$2.04 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$292,000.00
|
$1.03 M
|
$512,000.00
|
$394,000.00
|
$195,000.00
|
$65,000.00
|
| EBITDA |
-$102.27 M
|
-$62.03 M
|
-$49.86 M
|
-$36.63 M
|
-$70.00 M
|
-$18.39 M
|
| EBITDA Ratio |
0 |
0 |
-49.86 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
-49.86
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$12.59 M
|
$2.04 M
|
$210,000.00
|
-$2.73 M
|
$1.36 M
|
$38,000.00
|
| Income Before Tax |
-$89.97 M |
-$59.99 M |
-$49.65 M |
-$39.76 M |
-$68.84 M |
-$18.09 M |
| Income Before Tax Ratio
|
0
|
0
|
-49.65
|
0
|
0
|
0
|
| Income Tax Expense |
$239,000.00 |
$358,000.00 |
$508,000.00 |
$813,000.00 |
-$20,000.00 |
-$67,000.00 |
| Net Income |
-$90.21 M |
-$60.35 M |
-$50.16 M |
-$40.57 M |
-$68.82 M |
-$17.71 M |
| Net Income Ratio |
0 |
0 |
-50.16 |
0 |
0 |
0 |
| EPS |
-1.27 |
-1.67 |
-1.98 |
-1.61 |
-2.74 |
-0.74 |
| EPS Diluted |
-1.27 |
-1.67 |
-1.98 |
-1.61 |
-2.74 |
-0.74 |
| Weighted Average Shares
Out |
$71.26 M
|
$36.03 M
|
$25.27 M
|
$25.13 M
|
$25.10 M
|
$23.97 M
|
| Weighted Average Shares
Out Diluted |
$71.26 M
|
$36.03 M
|
$25.27 M
|
$25.13 M
|
$25.10 M
|
$23.97 M
|
| Link |
|
|
|
|
|
|
